Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides

被引:54
作者
Barg, J
Fride, E
Hanus, L
Levy, R
MatusLeibovitch, N
Heldman, E
Bayewitch, M
Mechoulam, R
Vogel, Z
机构
[1] WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL
[2] TEL AVIV UNIV,SCH MED,E WOLFSON MED CTR,CARDIOVASC & HYPERTENS RES LAB,HOLON,ISRAEL
[3] HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,JERUSALEM,ISRAEL
[4] ISRAEL INST BIOL RES,IL-70450 NESS ZIONA,ISRAEL
关键词
adenylate cyclase; anandamide; cannabinoid receptor; GTP-binding protein;
D O I
10.1016/0014-2999(95)00487-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have previously shown that the endogenous putative cannabinoid ligand arachidonylethanolamide (anandamide, 20:4, n - 6) induces in vivo and in vitro effects typical of a cannabinoid agonist. We now report that two other endogenous anandamides, docosatetraenylethanoiamide (anandamide, 22:4, n - 6) and homo-gamma-linolenylethanolamide (anandamide, 20:3, n - 6), have similar activities. The new anandamides bind to SV40-transformed African green monkey kidney cells transfected with the rat brain cannabinoid receptor cDNA and display K-I values of 253.4 +/- 41.1 and 244.8 +/- 38.7, respectively. The value found for arachidonylethanolamide was 155.1 +/- 13.8 nM. In addition, the new anandamides inhibit prostaglandin E(1)-stimulated adenylate cyclase activity in Chinese hamster ovary-K-1 cells transfected with the cannabinoid receptor, as well as in N(18)TG(2) mouse neuroblastoma cells that express the cannabinoid receptor naturally. The IC,, values for the inhibition of adenylate cyclase in transfected Chinese hamster ovary-K-1 cells were 116.8 +/- 8.7 and 109.3 +/- 8.6 nM for docosatetraenylethanolamide and homo-gamma-linolenylethanolamide, respectively. These values were similar to that obtained with arachidonylethanolamide (100.5 +/- 7.7 nM), but were significantly higher than the IC50 value observed with the plant cannabinoid Delta(9)-tetrahydrocannabinol (9.2 +/- 8.6 nM). The inhibitory effects of the anandamides on adenylate cyclase activity were blocked by pertussis toxin, indicating the involvement of pertussis toxin-sensitive GTP-binding protein(s). In a tetrad of behavioral assays for cannabinoid-like effects, the two new anandamides exerted similar behavioral effects to those observed with Delta(9)-tetrahydrocannabinol and arachidonylethanolamide: inhibition of motor activity in an open field, hypothermia, catalepsy on a ring, and analgesia on a hot plate.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 25 条
  • [1] NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC-ANTAGONIST ACTIVITIES
    ANKIER, SI
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1974, 27 (01) : 1 - 4
  • [2] [Anonymous], CANNABINOID RECEPTOR
  • [3] COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218
  • [4] ANANDAMIDE, AN ENDOGENOUS LIGAND OF THE CANNABINOID RECEPTOR, INDUCES HYPOMOTILITY AND HYPOTHERMIA IN-VIVO IN RODENTS
    CRAWLEY, JN
    CORWIN, RL
    ROBINSON, JK
    FELDER, CC
    DEVANE, WA
    AXELROD, J
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 46 (04) : 967 - 972
  • [5] DELEAN A, 1988, USERS GUIDE ALLFIT, P97
  • [6] ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR
    DEVANE, WA
    HANUS, L
    BREUER, A
    PERTWEE, RG
    STEVENSON, LA
    GRIFFIN, G
    GIBSON, D
    MANDELBAUM, A
    ETINGER, A
    MECHOULAM, R
    [J]. SCIENCE, 1992, 258 (5090) : 1946 - 1949
  • [7] EDDY NB, 1953, J PHARM, V98, P121
  • [8] ANANDAMIDE, AN ENDOGENOUS CANNABIMIMETIC EICOSANOID, BINDS TO THE CLONED HUMAN CANNABINOID RECEPTOR AND STIMULATES RECEPTOR-MEDIATED SIGNAL-TRANSDUCTION
    FELDER, CC
    BRILEY, EM
    AXELROD, J
    SIMPSON, JT
    MACKIE, K
    DEVANE, WA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) : 7656 - 7660
  • [9] PHARMACOLOGICAL ACTIVITY OF THE CANNABINOID RECEPTOR AGONIST, ANANDAMIDE, A BRAIN CONSTITUENT
    FRIDE, E
    MECHOULAM, R
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 231 (02) : 313 - 314
  • [10] FRIDE E, 1995, J PHARMACOL EXP THER, V272, P699